NEW YORK (GenomeWeb News) — Affymetrix today said that fourth-quarter revenue will likely fall 11.5 percent year over year, but because the company beat analysts’ estimates its shares skyrocketed.
 
Affy today said it expects total revenues for the three months ended Dec. 31, 2006, to be around $100 million compared with $111.5 million during the same period in 2005. However, analysts expected the company to post $99.5 million for the period.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.